Johnson and Johnson (JNJ) News

Johnson & Johnson to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th. Management...

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates

NYSE Content Advisory: Pre-Market update + Bank of America beats earnings estimates PR Newswire NEW YORK...

Form 8-K - Current report

Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24...

Johnson & Johnson Reports Q1 2025 Results

2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025...

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill

Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and...

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term...

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13th, 2025. Management will...

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and...

Form 8-K - Current report

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA® (lumateperone), the first and only U.S. FDA-approved...

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by...

Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts

Court ruling marks major victory for ovarian cancer patients as legal battle shifts to multidistrict litigation In a resounding victory for...

Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously...